Literature DB >> 12384514

Transforming growth factor-beta1 mediates cellular response to DNA damage in situ.

Kenneth B Ewan1, Rhonda L Henshall-Powell, Shraddha A Ravani, Maria Jose Pajares, Carlos Arteaga, Ray Warters, Rosemary J Akhurst, Mary Helen Barcellos-Hoff.   

Abstract

Transforming growth factor (TGF)-beta1 is rapidly activated after ionizing radiation, but its specific role in cellular responses to DNA damage is not known. Here we use Tgfbeta1 knockout mice to show that radiation-induced apoptotic response is TGF-beta1 dependent in the mammary epithelium, and that both apoptosis and inhibition of proliferation in response to DNA damage decrease as a function of TGF-beta1 gene dose in embryonic epithelial tissues. Because apoptosis in these tissues has been shown previously to be p53 dependent, we then examined p53 protein activation. TGF-beta1 depletion, by either gene knockout or by using TGF-beta neutralizing antibodies, resulted in decreased p53 Ser-18 phosphorylation in irradiated mammary gland. These data indicate that TGF-beta1 is essential for rapid p53-mediated cellular responses that mediate cell fate decisions in situ.

Entities:  

Keywords:  NASA Discipline Radiation Health; Non-NASA Center

Mesh:

Substances:

Year:  2002        PMID: 12384514

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

3.  Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.

Authors:  Shizhen Emily Wang; Archana Narasanna; Corbin W Whitell; Frederick Y Wu; David B Friedman; Carlos L Arteaga
Journal:  J Biol Chem       Date:  2007-01-04       Impact factor: 5.157

Review 4.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

Review 5.  The complexities of TGF-β action during mammary and squamous cell carcinogenesis.

Authors:  Erin C Connolly; Rosemary J Akhurst
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

Review 6.  Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas.

Authors:  Shisuo Du; Mary Helen Barcellos-Hoff
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

Review 7.  Targeting inflammatory pathways for tumor radiosensitization.

Authors:  Amit Deorukhkar; Sunil Krishnan
Journal:  Biochem Pharmacol       Date:  2010-06-30       Impact factor: 5.858

8.  MiR-663 inhibits radiation-induced bystander effects by targeting TGFB1 in a feedback mode.

Authors:  Wentao Hu; Shuai Xu; Bin Yao; Mei Hong; Xin Wu; Hailong Pei; Lei Chang; Nan Ding; Xiaofei Gao; Caiyong Ye; Jufang Wang; Tom K Hei; Guangming Zhou
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

9.  The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus.

Authors:  Franziska Pühringer-Oppermann; Mario Sarbia; Nicola Ott; Björn L D M Brücher
Journal:  Int J Colorectal Dis       Date:  2009-12-15       Impact factor: 2.571

10.  Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer.

Authors:  E L Milliken; K L Lozada; E Johnson; M D Landis; D D Seachrist; I Whitten; A L M Sutton; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.